首页> 外文期刊>Revista de Nefrologia Dialisis y Trasplante >Trasplante cardiorenal combinado en la enfermedad cardíaca y renal avanzada
【24h】

Trasplante cardiorenal combinado en la enfermedad cardíaca y renal avanzada

机译:联合心肾移植治疗晚期心肾疾病

获取原文
       

摘要

Introduction: Renal failure (RF) is a post cardiac transplantation predictor of morbimortality. The combined cardiorenal transplant (CCRTx) in cardiac transplantation (CTx) candidates with chronic renal disease is a therapeutic option. Our aim was to evaluate the CCRTx follow up outcomes in a single Centre. Methods: Between 2/1993 and 12/2014 we performed 442 CTx. Since 2006, 20 patients (p) underwent CCRTx using allografts from the same donor. The inclusion criteria were: RF with CrCl ≤ 40 mil/min or dialysis requirement in CTx candidates. All p received Thymoglobulin and immunosuppression with tacrolimus, mycophenolate mofetil and steroids.Median follow up: 46 months (7-96). Results: Mean age: 58±7 years, 85% were male. Mean Creatinine (Cr): 3,1±2,5 mg/dl and ClCr 27,5+10 mil/min. Three p required dialysis during the pre-transplantation phase and 4 p were under chronic dialysis. Etiologies: cardiomyopathies: coronary 10 p, noncoronary 9 p and re CTx, 1 p; nephropathies: nephroangiosclerosis 5 p, cardiorenal syndrome 10 p, diabetes 2 p, glomerulopathy 1 p, polycystosis 1 p and toxic nephritis 1 p. At 30 days and 1 year post CCRTx, Cr was 1,2±0,4 mg/dl and 1,1±0,2 mg/dl respectively. In-hospital mortality was 3/20 p (15%), 2 p due to sepsis and 1 p due to cardiac graft failure. Late mortality 5/17 p (29 %), 4p due to sepsis and 1 p due to liver sarcoma. Survival at 1 and 3 years was 76 and 72%, respectively. Conclusions: In our series CCRTx was a safe and effective treatment for CTx candidates with CrCl 40 ml/min.
机译:简介:肾衰竭(RF)是心脏移植后死亡率的预测指标。在患有慢性肾脏疾病的心脏移植(CTx)候选者中进行联合心脏肾移植(CCRTx)是一种治疗选择。我们的目标是在一个中心内评估CCRTx的随访结果。方法:在2/1993至12/2014之间,我们执行了442次CTx。自2006年以来,有20位患者(p)使用来自同一供体的同种异体移植物进行了CCRTx治疗。纳入标准为:CrCl≤40 mil / min的RF或CTx候选者的透析要求。所有患者均接受胸腺球蛋白和他克莫司,霉酚酸酯和类固醇的免疫抑制。中位随访时间:46个月(7-96岁)。结果:平均年龄:58±7岁,男性占85%。平均肌酐(Cr):3.1±2.5 mg / dl和ClCr 27.5 +10 mil / min。移植前需要进行3 p透析,而慢性透析需要4 p。病因:心肌病:冠状动脉10 p,非冠状动脉9 p,re CTx,1 p。肾病:肾血管硬化5 p,心肾综合征10 p,糖尿病2 p,肾小球病1 p,多囊病1 p和中毒性肾炎1 p。 CCRTx后30天和1年时,Cr分别为1,2±0.4 mg / dl和1,1±0.2 mg / dl。住院死亡率为3/20 p(15%),败血症为2 p,心脏移植失败为1 p。晚期死亡率为5/17 p(29%),败血症为4p,肝肉瘤为1p。 1年和3年生存率分别为76%和72%。结论:在我们的系列中,CCRTx是治疗CrCl <40 ml / min的CTx候选者的安全有效方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号